Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Improvement in quality of life impairment followed by relapse with 6-monthly periodic administration of omalizumab for severe treatment-refractory chronic urticaria and urticarial vasculitis.

Authors
Type
Published Article
Journal
Clinical and Experimental Dermatology
1365-2230
Publisher
Wiley Blackwell (Blackwell Publishing)
Publication Date
Volume
39
Issue
5
Pages
651–652
Identifiers
DOI: 10.1111/ced.12320
PMID: 24758481
Source
Medline
License
Unknown

Statistics

Seen <100 times